顧みられない熱帯病診断市場- 世界の産業規模、シェア、動向、機会、予測、疾患別、診断方法別、サービスタイプ別、最終用途別、地域別セグメント、競合、2020年～2030年

世界の顧みられない熱帯病診断市場は2024年に62億米ドルと評価され、2030年までのCAGRは4.09%で、予測期間中に目覚ましい成長を遂げると予測されています。

顧みられない熱帯病（Neglected Tropical Diseases：NTDs）とは、主に世界の低所得層や熱帯・亜熱帯地域の人々が罹患する感染症群を指します。これらの疾病は、社会から疎外され、貧困にあえぐ地域社会で蔓延していることが特徴で、適切なヘルスケア、清潔な水、衛生設備、予防対策へのアクセスが欠如していることが多いです。NTDsは、世界で最も貧しく社会から疎外された人々、特に農村部や都市のスラム地域に住む人々に、不釣り合いな影響を与えます。こうした地域社会では、基本的なヘルスケアサービスを受けられないことが多いです。NTDsは、細菌、ウイルス、寄生虫、原虫など、さまざまな感染因子によって引き起こされます。これらの病気のトランスミッションは、多くの場合、環境要因や蚊やハエなどの媒介虫と関連しています。NTDの擁護団体や啓発キャンペーンは、これらの病気に対する一般の人々や政治的認識を高める上で重要な役割を果たしてきました。その結果、診断や治療への取り組みに対する支援が高まっています。

市場促進要因

診断の進歩

主な市場課題

高感度で特異的な検査の欠如

主な市場動向

早期発見の重視

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の顧みられない熱帯病診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患別（デング熱、チクングニア熱、狂犬病、ブルーリ潰瘍、イチゴ腫、リンパ系フィラリア症、条虫症/嚢虫症、メジナ虫症、その他）
  • 診断方法別（従来型、分子/現代型）
  • サービスタイプ別（集中サービス、POCサービス）
  • 最終用途別（臨床検査室、病院/診療所、在宅ヘルスケア）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の顧みられない熱帯病診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の顧みられない熱帯病診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の顧みられない熱帯病診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の顧みられない熱帯病診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの顧みられない熱帯病診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の顧みられない熱帯病診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Coris Bioconcept
• Oscar medicare Pvt Ltd.
• DiaSys Diagnostics Systems GmbH

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Neglected Tropical Diseases Diagnosis Market was valued at USD 6.20 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.09% through 2030. Neglected Tropical Diseases (NTDs) refer to a group of infectious diseases that primarily affect populations in low-income and tropical or subtropical regions of the world. These diseases are characterized by their prevalence in marginalized and impoverished communities, often lacking access to adequate healthcare, clean water, sanitation, and preventive measures. NTDs disproportionately affect the world's poorest and most marginalized populations, particularly those living in rural or urban slum areas. These communities often lack access to basic healthcare services. NTDs are caused by a variety of infectious agents, including bacteria, viruses, parasites, and protozoa. The transmission of these diseases is often linked to environmental factors and vectors, such as mosquitoes or flies. NTD advocacy groups and awareness campaigns have played a significant role in increasing public and political awareness about these diseases. This has resulted in greater support for diagnosis and treatment efforts.

Key Market Drivers

Advancements in Diagnostics

Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs) have revolutionized NTDs diagnosis. They allow for the detection of the genetic material of pathogens with high sensitivity and specificity. Molecular diagnostics are particularly useful for diseases like Chagas disease and Leishmaniasis. For instance, according to a 2024 NCBI article, advancements in artificial intelligence are enhancing medical computer-aided diagnosis, improving accuracy, efficiency, and early disease detection for better patient outcomes.

Also, in May 2022, medical technology company Anitoa Systems launched a portable RT-PCR test for dengue virus detection, expanding its Maverick RT-PCR device line. This multiplex test detects multiple target genes linked to severe dengue, ensuring early and accurate diagnosis. Point-of-Care Testing (POCT) devices have been developed for various NTDs, enabling rapid and on-site diagnosis. These portable devices are especially valuable in remote and resource-limited settings where access to centralized laboratories is limited. Examples include rapid diagnostic tests for malaria and dengue. Serological tests detect specific antibodies produced by the immune system in response to infection. Advances in serological assays have improved their accuracy and made them more widely available for diagnosing diseases like schistosomiasis and lymphatic filariasis. Some NTDs can be diagnosed by detecting specific antigens produced by the pathogens. Antigen detection tests are valuable for diseases like African sleeping sickness and urinary schistosomiasis.

Key Market Challenges

Lack of Sensitive and Specific Tests

Many NTDs share symptoms with other diseases or have multiple stages, making accurate diagnosis difficult. When sensitive and specific tests are lacking, there's a higher risk of misdiagnosis or underdiagnosis, leading to delayed or inadequate treatment. Accurate diagnosis is essential for determining the appropriate treatment regimen. Without sensitive and specific tests, healthcare providers may resort to empirical treatment, which can result in unnecessary healthcare costs and potential drug resistance. NTDs control and elimination programs rely on accurate data to target affected populations effectively. Inaccurate diagnosis can lead to misallocation of resources, potentially slowing down progress in controlling these diseases. For tracking the prevalence and distribution of NTDs, sensitive and specific tests are crucial. Inaccurate diagnostic tools can lead to inaccurate disease surveillance data, hindering the ability to detect outbreaks or changes in disease patterns. Diagnostic tools are fundamental in research efforts related to NTDs, including drug and vaccine development. Insensitive or nonspecific tests can slow down the research process and hinder the identification of potential therapeutic targets. Patients may undergo multiple tests, sometimes invasive, to confirm an NTD diagnosis due to the lack of definitive tests. This can result in a physical and psychological burden on affected individuals. Limited healthcare resources in endemic regions should be used efficiently. Sensitive and specific tests are essential for targeting interventions to those who need them most, thereby optimizing resource allocation.

Key Market Trends

Focus on Early Detection

Early detection allows for prompt initiation of treatment, which can lead to better outcomes for patients. For many NTDs, early treatment can prevent disease progression and complications. Early diagnosis and treatment can help break the cycle of transmission of NTDs. By identifying and treating infected individuals early, there is a reduced risk of spreading the disease to others through vectors or direct contact. Some NTDs, such as lymphatic filariasis and leprosy, can cause disabling conditions if not treated early. Early detection and intervention can prevent or reduce disability and improve the quality of life for affected individuals. Early detection can be cost-effective in the long run. It reduces the need for more extensive and expensive treatments that may be required if NTDs are diagnosed at a later stage. Timely diagnosis contributes to the success of NTDs control and elimination programs. Early detection allows for more targeted and efficient interventions, which can accelerate progress toward achieving disease control goals. Some NTDs are associated with social stigma and discrimination. Early diagnosis and treatment can help individuals avoid the social consequences of living with untreated NTDs. Advances in point-of-care diagnostic technologies make it possible to diagnose NTDs quickly and accurately in resource-limited settings, enabling immediate treatment and reducing the need for follow-up visits.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• DiaSys Diagnostics Systems GmbH
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Oscar Medicare Pvt Ltd.
• Coris BioConcept

Report Scope:

In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Diseases Diagnosis Market, By Disease:

• Dengue
• Chikungunya
• Rabies
• Buruli Ulcer
• Yaws
• Lymphatic Filariasis
• Taeniasis/Cysticercosis
• Dracunculiasis
• Others

Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method:

• Conventional
• Molecular/Modern

Neglected Tropical Diseases Diagnosis Market, By Service Type:

• Centralized Service
• POC Service

Neglected Tropical Diseases Diagnosis Market, By End-Use:

• Clinical Labs
• Hospital/Clinics
• Home Healthcare

Neglected Tropical Diseases Diagnosis Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.

Available Customizations:

Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Diseases Diagnosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
  • 5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
  • 5.2.3. By Service Type (Centralized Service, POC Service)
  • 5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Diagnostic Method
  • 6.2.3. By Service Type
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Diagnostic Method
      • 6.3.1.2.3. By Service Type
      • 6.3.1.2.4. By End Use
  • 6.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Diagnostic Method
      • 6.3.2.2.3. By Service Type
      • 6.3.2.2.4. By End Use
  • 6.3.3. Australia Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Diagnostic Method
      • 6.3.3.2.3. By Service Type
      • 6.3.3.2.4. By End Use
  • 6.3.4. Japan Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease
      • 6.3.4.2.2. By Diagnostic Method
      • 6.3.4.2.3. By Service Type
      • 6.3.4.2.4. By End Use
  • 6.3.5. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease
      • 6.3.5.2.2. By Diagnostic Method
      • 6.3.5.2.3. By Service Type
      • 6.3.5.2.4. By End Use

7. Europe Neglected Tropical Diseases Diagnosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Diagnostic Method
  • 7.2.3. By Service Type
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Diagnostic Method
      • 7.3.1.2.3. By Service Type
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Diagnostic Method
      • 7.3.2.2.3. By Service Type
      • 7.3.2.2.4. By End Use
  • 7.3.3. Spain Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Diagnostic Method
      • 7.3.3.2.3. By Service Type
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Diagnostic Method
      • 7.3.4.2.3. By Service Type
      • 7.3.4.2.4. By End Use
  • 7.3.5. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Diagnostic Method
      • 7.3.5.2.3. By Service Type
      • 7.3.5.2.4. By End Use

8. North America Neglected Tropical Diseases Diagnosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Diagnostic Method
  • 8.2.3. By Service Type
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Diagnostic Method
      • 8.3.1.2.3. By Service Type
      • 8.3.1.2.4. By End Use
  • 8.3.2. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Diagnostic Method
      • 8.3.2.2.3. By Service Type
      • 8.3.2.2.4. By End Use
  • 8.3.3. Canada Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Diagnostic Method
      • 8.3.3.2.3. By Service Type
      • 8.3.3.2.4. By End Use

9. South America Neglected Tropical Diseases Diagnosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Diagnostic Method
  • 9.2.3. By Service Type
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Diagnostic Method
      • 9.3.1.2.3. By Service Type
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Diagnostic Method
      • 9.3.2.2.3. By Service Type
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Diagnostic Method
      • 9.3.3.2.3. By Service Type
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Neglected Tropical Diseases Diagnosis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Diagnostic Method
  • 10.2.3. By Service Type
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Diagnostic Method
      • 10.3.1.2.3. By Service Type
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Diagnostic Method
      • 10.3.2.2.3. By Service Type
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Diagnostic Method
      • 10.3.3.2.3. By Service Type
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. F. Hoffmann-La Roche Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Thermo Fisher Scientific Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. ZeptoMetrix LLC
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. InBios International, Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Genome Diagnostics Pvt. Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Omega Diagnostics Group Plc
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Coris Bioconcept
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Oscar medicare Pvt Ltd.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. DiaSys Diagnostics Systems GmbH
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer